Media
ViAqua Therapeutics Announces $8.25M Investment Led by S2G Ventures to Scale RNA-Based Solutions in Aquaculture
September 5, 2023
HAIFA, Israel, Sept. 5, 2023 /PRNewswire/ -- ViAqua Therapeutics, a biotechnology company and developer of an orally administered RNA-particle platform to promote and improve animal health in aquaculture, announced it has completed a US$8.25M round led by S2G Ventures with participation from Rabo Ventures, The Trendlines Group Ltd., Agriline Limited, Nutreco, I-Lab Angels and Circle Investments LLC.
Thai Union Corporate Venture Fund Expands Into Biotechnology; Invests in RNA-based Aquaculture Health Platform
June 10, 2021
Thai Union Group PCL has invested in biotechnology company ViAqua Therapeutics through its venture fund, joining other industry-leading strategic and financial partners in backing the start-up. At left: Thai Union Group PCL CEO Thiraphong Chansiri
News of this announcement also appeared on —
ViAqua Therapeutics Announces $4.3 Million Investment led by S2G Ventures for its RNA-based Aquaculture Health Platform
June 9, 2021
Financing will support the commercialization of the first product aimed at improving health in shrimp and support the development of additional products to improve aquatic animal health and nutrition.
News of this announcement also appeared in —
Nutreco investment
July 03, 2019
Nutreco has invested in Israeli startup ViAqua as part of its focus on combatting disease in the aquaculture industry. ViAqua is developing the first orally-administered treatment for shrimp that improves resistance to viral diseases, including White Spot Syndrome Virus (WSSV), and prevents viral epidemics. Nutreco has taken a meaningful minority share that will conditionally grow over time.